Results from a Phase I/II study of the Novartis Janus kinase (JAK) inhibitor with the investigational name INC424 (also known as INCB018424 and INCB18424) were published in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis[2].

Forest Laboratories, Inc. (NYSE: FRX) has finalized a previously reported agreement-in-principle to resolve all aspects of the investigations led by the United States Department of Justice (DOJ) and the United States Attorney's Office for the District of Massachusetts that began in January 2004 relating to past marketing, sales, and other activities in connection with Celexa(R), Lexapro(R), and a formulation of Levothroid(R) that Forest ceased distributing in 2003.

Abbott (NYSE: ABT) has been named one of the 100 Best Companies by Working Mother magazine. This was the tenth consecutive year that Abbott has been included on the prestigious list, which recognizes companies for leadership in providing family-friendly benefits, programs and workplace culture.

Abbott was included on both the Dow Jones Sustainability World Index and North America Index for the sixth consecutive year. The Dow Jones Sustainability Indexes (DJSI) recognize the leading companies in each industry sector for responsible economic, environmental and social performance.

The Bone and Joint Decade (BJD) international initiative and GlaxoSmithKline (GSK) announced the launch of the LIBERATE™ joint pain management programme during the BJD's World Conference in Lund, Sweden.

Genzyme Corporation (Nasdaq: GENZ) today announced that it has entered into an asset purchase agreement under which Laboratory Corporation of America Holdings (LabCorp) will acquire Genzyme Genetics for $925 million in cash.

New Phase III data presented by Novartis Vaccines indicate that the investigational Multicomponent Meningococcal Serogroup B Vaccine (4CMenB) has the potential to be the first broad-coverage vaccine against the dynamic and deadly meningococcal B (MenB) disease.